Skip to search formSkip to main contentSkip to account menu

ASA 404

Known as: ASA-404, ASA404 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

vadimezan

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Coumarins, Xanthones and Related Compounds
It has long been known that coumarins (γ-pyrones) and xanthones (α-pyrones) together form a large class of naturally occurring… 
2012
2012
Mass balance, excretion and metabolism of [14C] ASA404 in cancer patients in a phase I trial
PurposeTo determine the mass balance, excretion and metabolism of the small molecule flavonoid tumour vascular disrupting agent… 
2011
2011
Clinical development of vascular disrupting agents: what lessons can we learn from ASA404?
Review
2011
Review
2011
Clinical trials of vascular disrupting agents in advanced non--small-cell lung cancer.
Review
2011
Review
2011
Preclinical efficacy of vascular disrupting agents in non-small-cell lung cancer.
2009
2009
Acute vascular disruption by 5,6-dimethylxanthenone-4-acetic Acid in an orthotopic model of human head and neck cancer.
The sustenance of most solid tumors including head and neck cancers (HNCs) is strongly dependent on the presence of a functioning… 
Review
2009
Review
2009
Angiogenesis inhibitors and vascular disrupting agents in non-small cell lung cancer.
Most patients diagnosed with non-small cell lung cancer (NSCLC) have advanced disease. Chemotherapy has apparently reached a… 
Review
2008
Review
2008
ASA404: update on drug development
Background: Interrupting tumour blood flow and delivery of nutrients to cause tumour death is the aim of antiangiogenic and… 
2008
2008
Addition of DMXAA (ASA404) to docetaxel in patients with hormone-refractory metastatic prostate cancer (HRMPC): update from a randomized, phase II study
5007 Background: DMXAA (ASA404) is a novel tumor vascular disrupting agent. In animal models DMXAA has synergistic anti-tumor… 
2008
2008
Comparison of safety and efficacy between squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of DMXAA (ASA404)
8072 Background: DMXAA (ASA404) is a tumor vascular disrupting agent recently evaluated in phase II trials in NSCLC. A randomized… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)